p53 tumor suppressor is a subject of several posttranslational modi®cations, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modi®cation of p53 at lysine 386 by SUMO-1 was recently identi®ed. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-de®cient p53 mutant, K386R. No dierences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no eect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 colocalized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-de®cient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modi®cation of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation. Oncogene (2001) 20, 2587 ± 2599.
Introduction
The p53 protein is encoded by a tumor suppressor gene, which is lost or inactivated in more than 50% of human cancers (Hollstein et al., 1996) . Inactivation of the p53 pathway in tumors is associated with genomic instability, resistance to treatment, and poor prognosis (reviewed in Kirsch and Kastan, 1998) .
p53 exerts its tumor suppressor function by being a key player in regulation of cellular response to genotoxic stress. Under normal conditions, the cellular level of p53 is low due to its rapid proteosomal degradation (reviewed in Momand et al., 2000) . In response to a variety of stresses, including DNA damage, ribonucleotide depletion, mitotic spindle damage, redox modulation, cell detachment, hypoxia, activation of oncogenes, etc., p53 protein is stabilized and accumulates in the nucleus (reviewed in Giaccia and Kastan, 1998) and acts as a transcription factor. Altered expression of a number of p53-responsive genes is, at least in part, responsible for the p53-dependent growth arrest or apoptosis occurring in the cell as a result of stress (reviewed in Sionov and .
Post-translational modi®cations play important roles in regulating activation of p53 (reviewed in Lakin and Jackson, 1999) . In vivo, p53 can be phosphorylated on serines 15, 20, 33, 37 and 392 in response to DNA damage by several protein-kinases, including DNA-PK (DNA-activated protein kinase), ATM kinase (the product of the gene mutated in ataxia telangiectasia), ATR kinase (ATM-Rad3-related), Chk1 and Chk2/ Cds1 (checkpoint kinase 1 and 2) (Chehab et al., 2000; Shieh et al., 2000) . Some of these kinases are involved in the detection, signaling, and/or repair of DNA damage. p53 can also be dephosphorylated at Ser376 in response to DNA damage (Waterman et al., 1998) . However, the importance of phosphorylation in p53 function remains controversial: several reports have shown that p53 mutations at one, two, or all known phosphorylation sites have no dramatic eect on the ability of p53 to activate transcription or its ability to be stabilized in response to DNA damage (Blattner et al., 1999; Ashcroft et al., 1999) .
Acetylation of p53 at Lys373/Lys382 and Lys320 by transcriptional co-activators, p300/CBP and PCAF respectively, enhances sequence speci®c DNA binding in vitro. In vivo, acetylation of these sites is increased in response to DNA-damaging agents (Liu et al., 1999) and overexpression of p300/CBP increases transactivation by p53 (Gu et al., 1997; Lill et al., 1997) .
Ubiquitination also plays a role in regulating p53 function as p53 is rapidly targeted for degradation by ubiquitin-mediated proteolysis (reviewed in Kubbutat and Vousden, 1998) . Degradation of p53 is regulated by its interaction with MDM2 (Haupt et al., 1997) , which functions as an E3 ubiquitin ligase for p53 (Honda et al., 1997) . MDM2 also shuttles p53 from the nucleus to the cytoplasm where degradation of p53 is thought to take place (Roth et al., 1998) . MDM2 is itself transcriptionally regulated by p53, establishing a negative feed back loop (reviewed in Piette et al., 1997) .
p53 was recently found to be covalently modi®ed by SUMO-1 (Small Ubiquitin-related Modi®er) (Rodriguez et al., 1999; Gostissa et al., 1999) . SUMO-1, also known as PIC1 (PML-interacting clone 1) (Boddy et al., 1996) , UBL1 (ubiquitin-like 1) (Shen et al., 1996) , Sentrin (Okura et al., 1996) , GMP1 (GAP modifying protein 1) (Matunis et al., 1996) , and, in yeast, SMT3 (Meluh and Koshland, 1995) , is a protein of 101 amino acid that has low (18%) but signi®cant homology to ubiquitin (Saitoh et al., 1997) . SUMO-1 is found conjugated with a growing list of proteins with distinct functions, such as RanGAP1 (Ran GTPase activating protein 1) (Mahajan et al., 1997) , IkBa (Desterro et al., 1998) , PML (Promyelocytic Leukemia Protein) (Sternsdorf et al., 1997) , SP100 (Sternsdorf et al., 1999) , HIPK2 (HomeodomainInteracting Protein Kinase 2) (Kim et al., 1999) and Topoisomerase I (Mao et al., 2000) . Modi®cation by SUMO-1, termed sumoylation, is thought to be enzymatically similar to ubiquitination in terms of requiring an E1 heterodimeric enzyme, SAE1/SAE2 in mammals and Aos1/Uba2 in yeast, and an E2 enzyme, UBC9. An E3 enzyme has not been identi®ed and is not required for in vitro sumoylation (Okuma et al., 1999) . Unlike ubiquitination, where proteins are frequently linked to multiple ubiquitin molecules, most of the SUMO-1 targets are conjugated to only one molecule of SUMO-1, with the exception of PML which is conjugated to three molecules at three separate sites (Kamitani et al., 1998) . Also unlike ubiquitination, modi®cation by SUMO-1 does not target proteins for degradation but modi®es their properties in dierent ways, such as increasing protein stability or altering intracellular localization (Mahajan et al., 1997; Desterro et al., 1998; Kim et al., 1999; Kamitani et al., 1998; Muller et al., 1998) . For example, it was recently shown that sumoylation of MDM2 competes with its ubiquitination and leads to MDM2 stabilization. This results in more ecient p53 degradation and a decrease in the ability of p53 to mediate apoptosis (Buschmann et al., 2000) .
We have isolated SUMO-1 as an interactor of p53 by the yeast two-hybrid screen and con®rmed Lys386 as the main site of sumoylation in mammalian cells. In addition, we found that the amount of SUMO-1-conjugated p53 increases in 293 cells after genotoxic stress. Using cell fractionation, we showed that the SUMO-1 conjugated form of p53 could only be found in the nucleus tightly bound to chromatin. Indirect immuno¯uoresence and confocal microscopy revealed that SUMO-1 and p53 co-localize in the cells: in PML nuclear bodies in 293 cells and in the nucleoli in MCF7 cells. However, the p53 mutant de®cient in sumoylation, K386R, showed a similar pattern of nuclear localization, indicating that SUMO-1 modi®cation is not required for targeting p53 to the nucleus and to the nucleoli. Contrary to what was reported by others, we did not observe an increase in the transactivation of p53 by SUMO-1. We also found that the sumoylationde®cient p53 mutant is as transcriptionally active, and can suppress cell growth as eciently as the wild type protein leaving open the question about a possible functional role of p53 sumoylation.
Results
p53 is covalently modified by SUMO-1 at lysine 386 p53, with a deletion of the ®rst 72 amino acids comprising the transactivation domain, was used as bait to screen a mouse brain cDNA library in a LexA yeast two-hybrid system (Finley and Brent, 1995) . SUMO-1 was among the isolated clones, suggesting that p53 may be modi®ed by SUMO-1.
SUMO-1 is known to conjugate with lysine residues of its target proteins via its C-terminus, forming isopeptide bonds (Mahajan et al., 1997) . SUMO-1 conjugated proteins can usually be detected in the lysate only if lysis is done in the presence of SDS (Desterro et al., 1998) . SUMO-1 has a calculated size of 11.5 KDa but SUMO-1 conjugated proteins run in the gel as if they would have additional 20 KDa (Mahajan et al., 1997) . Two bands, migrating as 53 and 73 KDa proteins, were detected in the SDS-containing lysates of 293 cells by polyclonal antibodies to p53, while only a 53 KDa band was seen in the lysate without SDS (Figure 1a ). This result was con®rmed with monoclonal DO-1 antibodies to p53.
To determine whether the 73 KDa band is p53-speci®c, we analysed two human p53-null cell lines (osteosarcoma, Saos-2 and non-small cell lung carcinoma cells, H1299) that were transiently transfected with pCDNA3, expressing wild type human p53 protein, and lysed with or without SDS. Western immunoblotting with DO-1 antibodies con®rmed that the 73 KDa band could only be detected in the cells transfected with p53 and lysed in the presence of SDS (Figure 1b) . In all cases, this slow migrating form of p53 was much less abundant than the major 53 KDa band.
In order to determine whether SUMO-1 is indeed a part of the 73 KDa protein, we`tagged' SUMO-1 protein at its N-terminus with an HA (hemagglutinin) tag cloned in frame with full-length cDNA of SUMO-1. This construct was transfected into 293 cells, which were then analysed by Western immunoblotting with anti-HA antibodies. A ladder of bands, representing SUMO-1 conjugated proteins, was recognized only in cells transfected with HA-SUMO-1 lysed in the presence of SDS, as was observed before (Desterro et al., 1998) . SDS lysate was diluted, immunoprecipitated with DO-1 antibodies and the precipitates were probed with anti-HA antibodies on Western blots. A 73 KDa band was detected only in the DO-1 antibody precipitates and only from the cells transfected with p53 modification by SUMO-1 SSS Kwek et al HA-SUMO-1 (Figure 1c ). Protein with similar mobility was also detected by anti-p53 and anti-SUMO-1 antibodies. This data con®rms that the 73 KDa band is in fact SUMO-1-conjugated p53. It is noteworthy that several bands corresponding to higher molecular weight proteins were also detected with anti-HA antibodies in DO-1 precipitates. These could be other SUMO-1 conjugated proteins that coprecipitated with p53. Mdm2 could be one of the candidates since it was recently shown that this p53 interactor is also a subject of sumoylation (Buschmann et al., 2000) .
Analysis of sumoylation sites of several proteins de®ned a weak consensus sequence for the conjugation site of SUMO-1 (Desterro et al., 1998; Figure 2a) . Human p53 has two lysine residues at amino acids 292 and 386 that are in the right context for potential sumoylation (Figure 2a ). Using in vitro SUMO-1 conjugation assay of wild type p53 and mutants with lysine to arginine substitution at these sites, we showed that lysine 386 and not lysine 292 is the SUMO-1 conjugation site (Figure 2b ). Transient transfection of mutants in Saos-2 and H1299 cells also showed that sumoylation of K386R mutant was also strongly suppressed in vivo (Figure 2c ). These observations con®rm the conclusion of Rodriguez et al. (1999) and Gostissa et al. (1999) who de®ned lysine 386 as the major sumolyation site in p53 protein. It is noteworthy, however, even in the case of K386R mutant, we could observe a weak higher molecular weight band in sumoylation p53 assays both in vitro and in vivo (Figure 2b,c) . This indicates that, while lysine 386 is the preferential site for SUMO-1 conjugation in p53 protein, another site can be utilized in the absence of lysine 386, though much less eectively.
DNA-damage causes an increase in the SUMO-1 conjugated form of p53
Changes in the level of sumoylated p53 in response to DNA damage might indicate a potential signi®cance of this modi®cation. 293 cells were treated with doxorubicin or UV light, collected at several time points, and analysed by Western blot with DO-1 antibodies. Although the amount of p53 did not change, the amount of sumoylated p53 increased after treatment with doxorubicin and UV light (Figure 3 ). However, we were unable to detect any SUMO-1 conjugated p53 in 12-1 (an immortalized mouse The SDS content in the cell lysate was diluted 10 times with PBS/0.5%NP40 with protease inhibitors and subjected to immunoprecipitation with DO-1 antibodies or non-speci®c mouse IgG. Immunoprecipitates were fractionated on 12% SDS ± PAGE and Western blot detection was ®rst carried out with anti-HA antibodies. The membrane was stripped of anti-HA antibodies and reprobed with biotinlyated anti-p53 antibodies. The membrane was stripped again and probed with anti-SUMO-1 antibodies ®broblast cell line), MCF7 (a breast carcinoma cell line), or HT1080 (a colon carcinoma cell line), even when p53 protein was induced by genotoxic stress. This might simply re¯ect a limited sensitivity of Western blot, which is incapable of detecting a minor fraction of SUMO-1-conjugated p53, if p53 is not highly overexpressed. In fact, 293 cells express a high amount of wild type p53 that is not toxic for the cells because of the presence of adenovirus type 5 DNA (Graham et al., 1977; Carter et al., 1987) , which expresses proteins E1A and E1B that stabilize and inactivates transactivation by p53, respectively (Debbas and White, 1993) . Nevertheless, treatment with DNA-damaging agents results in an increase in acetylation of p53 in 293 cells (see Cell Signaling Technology Inc. catalog), indicating that p53 in these cells is susceptible to post-translational modi®cations.
p53 conjugated with SUMO-1 is in the chromatin-bound fraction of the nucleus There could be two alternative explanations to the fact that SUMO-1 conjugated proteins could only be detected in SDS-containing cell lysate. It might re¯ect tight association of such proteins with nuclear structures that are resistant to non-ionic detergents. Alternatively, it was suggested that SDS might act as an inhibitor of speci®c hydrolases that otherwise cleave the isopeptide bonds between SUMO-1 and the target proteins in cell lysates (Desterro et al., 1998) . SUMO-1 hydrolases were recently identi®ed both in yeast (Li and Hochstrasser, 1999) and in mammalian cells (Suzuki et al., 1999; Gong et al., 2000) . We used several experimental approaches to dierentiate between these possibilities.
First, sumoylated p53 is still not detected in lysate prepared without SDS but in the presence of the hydrolase inhibitor, N-ethylmaleimide (NEM) (Suzuki et al., 1999) . Second, SUMO-1 conjugated p53 was detected in the insoluble fraction separated from cells lysed in the absence of SDS and NEM and dissolved in SDS-sample buer. Third, sumoylated p53 was also detected when the insoluble fraction was sonicated in the absence of SDS and NEM ( Figure 4a ). Thus, these experiments indicated that SUMO-1 conjugated p53 is not a subject of hydrolase cleavage in the absence of SDS and is tightly bound to some nuclear structures resistant to non-ionic detergents.
We applied biochemical cell fractionation of 293 cells to further characterize the localization of SUMO-1 conjugated p53. Equivalent proportions of cytoplasmic and nuclear fractions were probed with p53 antibodies by Western immunoblotting. The results obtained S-Met-labeled proteins from empty vector, pCDNA3 expressing wild type human p53, K292R mutant, K386R mutant or K292R/K386R double mutant in the absence or presence of puri®ed SUMO-1 and UBC9 proteins. Reaction mixtures were fractionated on 4 ± 20% SDS ± PAGE and SUMO-1 conjugated p53 was detected by autoradiography. (c) Saos-2 cells were transiently transfected with empty vector, wild type p53, or mutants as mentioned above in (b). Non-SDS or SDS-containing cell lysates were obtained 48 h after transfection and fractionated on 4 ± 20% SDS ± PAGE. SUMO-1 conjugated p53 was detected by Western blotting with DO-1 antibodies Figure 3 Doxorubicin and UV increase SUMO-1 conjugated p53 in 293 cells. 293 cells were untreated or treated with 400 ng/ ml of doxorubicin (a) or 40 s of UV irradiation (b) and cells were lysed in the absence or presence of SDS after the indicated number of hours. Cell lysates were fractionated on 4 ± 20% SDS ± PAGE. Western blot was ®rst carried out with DO-1 antibodies to reveal SUMO-1 conjugated p53 (top panel). Lower exposure revealed the levels of p53 (middle panel). The membrane was then stripped and Western blot detection was carried out with antinucleosporin p62 antibodies to check that the same amount of protein was loaded (lower panel). This experiment was carried out at least twice p53 modification by SUMO-1 SSS Kwek et al
showed that SUMO-1 conjugated p53 is located in the nucleus (Figure 4b ). Further, puri®ed nuclei were treated with DNase and RNase to release soluble nuclear contents (Kay et al., 1972; Gerace et al., 1982) . DNase/RNase-soluble nuclear fraction was isolated and the pellet was treated with low salt (0.5 M) buer to dissociate weakly bound proteins (such as cytochrome P450), followed by extraction in high salt buer (2 M) which dissociates chromatin from the nuclear membrane (Snow et al., 1987) . None of these treatments should dissociate proteins strongly bound to the nuclear membrane.
Western blot analysis of the isolated fractions showed that SUMO-1 conjugated p53 was solubilized only by the last treatment with high salt (Figure 4b ). Several other cellular proteins were probed in the same fractions to compare their behavior during isolation with SUMO-1 conjugated p53. Paxillin, a cytoskeleton protein, was used as a control of nuclear-cytoplasmic separation. Nuclear membrane proteins lamin A and C (Holtz et al., 1989) remained in the pellet even after extraction with high salt. This suggests that SUMO-1 conjugated p53 is not tightly bound to the nuclear membrane. Staining with antibodies against p14 Arf , which was found in the nucleoplasm as well as the nucleoli (LindstroÈ m et al., 2000) , showed that it is mainly eluted into the supernatant by DNase/RNase treatment, with a minor fraction remaining in the pellet after high salt treatment. Staining with antibodies against histone H4, a chromatin-associated protein, showed that it is in the nucleus. It is not eluted by DNase/RNase treatment or by low salt, but it is eluted into the supernatant by treatment with high salt, thus behaving similarly to sumoylated p53. This suggests that sumoylated p53 may be a chromatin-bound protein.
SUMO-1 modification of p53 at lysine 386 is not required for targeting p53 to the nucleoli p53 has been observed in subnuclear structures like the PML bodies and the nucleoli (Rubbi and Milner, 2000) . Using indirect immuno¯uoresence, we showed that p53 co-localized with SUMO-1 and PML in 293 cells. p53 and SUMO-1 did not colocalize with ®brillarin, a protein found only in the nucleoli and coiled bodies (Figure 5a , Reimer et al., 1987) . This suggests that SUMO-1 modi®ed p53 may be localized to PML bodies in 293 cells. However, p53 and SUMO-1 co-localized predominantly in the nucleoli in MCF7 cells (Figure 5b ) and HT1080 cells (data not shown), as demonstrated by staining with Dapi (4,6-diamidino-2-phenylindole). This dierence in localization could be explained by the presence of E1B in 293 cells: E1B has been shown to localize in PML bodies (Leppard and Everett, 1999) and could have relocalized p53 to PML bodies in 293 cells. To determine the location of p53 in subnuclear structures in other cell types, we transfected p53 into p53-null cells, Saos-2 and H1299 cells. We observed that p53 remains in the nucleoplasm in Saos-2 and H1299 cells (Figure 6a ). Co-transfection of p53 with MDM2 and p14
Arf relocalized p53 to subnuclear structures as was observed before (Zhang and Xiong, 1999) . Immuno¯uoresence staining showed co-localization of p53 and SUMO-1 with ®brillarin, showing that p53 localizes in the nucleoli in Saos-2 cells (Figure 6b ). SUMO-1 modi®cation was shown to be important for targeting various proteins to distinct subnuclear structures (Mahajan et al., 1997; Kamitani et al., 1998) . SUMO-1 modi®cation might be required for targeting p53 to the nucleoli. Although antibodies used for immuno¯uoresence are directed against total p53 or 2) ; or 293 cells were lysed with lysis buer containing 1 mM NEM (Sigma), in the absence or in the presence of SDS ( lanes 3 and 4) ; or the pellet obtained after lysis of 293 cells with no SDS was sonicated and further fractionated into supernatant and pellet (lanes 5 and 6); or lysed with lysis buer containing SDS as control for presence of SUMO-1 conjugated p53 (lane 7). The same cellular proportion for each fractionation was run on 12% SDS ± PAGE. Western blotting was carried out with DO-1 antibodies. (b) 293 cells were fractionated into cytoplasmic fraction and nuclear fraction (lanes 1 and 2) . The nuclei were further fractionated into DNase/RNase soluble fraction in the supernatant (S) and insoluble fraction in the pellet (P) (lanes 3 and 4). The DNase/RNase insoluble fraction was further treated with 0.5 M NaCl (lanes 5 and 6) or 2 M NaCl (lanes 7 and 8) and separated into supernantant and pellet. The same cellular proportion for each fractionation was run on 12% SDS ± PAGE. Western blot was carried out with the indicated antibodies SUMO-1 and cannot detect a minor fraction of SUMO-1 conjugated p53, they allowed us to localize these proteins in subcellular structures. Comparing the localization of wild type p53 and K386R mutant would allow us to address if SUMO-1 modi®cation is required for targeting p53 to these structures. To determine if SUMO-1 modi®cation is required for targeting p53 to the nucleoli, we co-transfected sumoylation-de®cient K386R p53 mutant, MDM2, and p14
Arf into Saos-2 and H1299 cells. K386R mutant co-localized in the nucleoli with SUMO-1 (Figure 6a,b) . The SUMO-1 detected was probably that which is conjugated to MDM2, as a large amount of MDM2 is sumoylated in vivo (Buschmann et al., 2000) . This shows that SUMO-1 modi®cation at lysine 386 is not required for targeting p53 to the nucleoli. Arf expressing plasmids. Cells were ®xed 24 h after transfection. Indirect immuno¯uoresence co-staining was carried out as described for Figure 5a . Superimposition of triple staining revealed co-localization of p53 and SUMO-1, and ®brillarin was observed to surround p53 and SUMO-1 proteins Overexpression of SUMO-1 increases the proportion of sumolyated p53 but does not affect transactivation by p53
In order to determine if SUMO-1 modi®cation has any eect on the transactivation of p53, we co-transfected Saos-2 cells with the plasmids expressing p53, SUMO-1, AdaCAT, or pWafCAT reporters under the p53 responsive promoter of the adenosine deaminase gene or the Waf-1/p21 gene respectively. Our results showed that co-expression of SUMO-1 with p53 did not increase transactivation by p53 in Saos-2 cells (Figure  7a,b) . It is noteworthy that broad variation in SUMO-1/p53 plasmid ratio used in transfection (from 10 : 1 to 1000 : 1) did not change this negative result. p300, a transcriptional co-activator of p53 (Avantaggiati et al., 1997) , increased transactivation by p53, as shown in Figure 7b . Furthermore, K386R mutant was as active as wild type p53 in transactivating the p53 responsive promoter. The same results were obtained in H1299 cells (data not shown).
These negative results could be explained by our inability to increase the proportion of sumoylated p53 in co-transfection experiments. In fact, free SUMO-1 protein can be detected in Saos-2 cells (Figure 7a ) making it questionable whether one could modulate the levels of sumoylation by co-transfection with a SUMO-1-expressing plasmid. To overcome this obstacle, we used a SUMO-1 construct (SUMO-4aa) with a deletion of the last four amino acids in a transactivation assay: it was shown that cleavage of the last four amino acids was required for the activation of SUMO-1 protein (Mahajan et al., 1997; Kamitani et al., 1997) . As a negative control, we used another SUMO-1 construct (SUMO-6aa) with deletion of the last six amino acids, which was shown previously to be defective in sumoylation . SUMO-4aa but not wild type SUMO-1 or SUMO-6aa caused an increase in the levels of sumoylated p53 (Figure 8a) . Nevertheless, no dierence in transactivation by p53 was observed between SUMO-4aa and SUMO-6aa (Figure 8b) , showing again that SUMO-1 does not appear to modulate transactivation by p53.
Sumoylation-deficient p53 is similar to wild type p53 in cell growth suppression
In order to test the importance of sumoylation in p53-mediated regulation of cell proliferation, we compared the eects of K386R mutant and wild type p53 on colony growth of Saos-2 and H1299 cells. Cells transfected with wild type p53 produced fewer colonies compared to empty vector, showing that p53 is growth suppressive in these cells. Suppression of colony growth by K293R, K386R and K293R/K386R mutants was similar to that by wild type p53, indicating that sumoylation-de®cient p53 at lysine 386 suppresses growth as eciently as wild type p53. K320R mutant has a lysine to arginine mutation in the major nuclear localization signal of p53 that prevents p53 protein from translocating into the nucleus (Shaulsky et al., 1990) . Suppression of colony growth was completely abrogated in K320R mutant, which produced as many colonies as empty vector (Figure 9 ).
Discussion
Interaction of p53 with SUMO-1 in yeast suggested that p53 could be a target of naturally occurring sumoylation in mammalian cells. In fact, recently Figure 7 Co-expression of SUMO-1 with p53 does not modulate transactivation by p53. (a) CAT assay on cell lysates from Saos-2 co-transfected with AdaCAT reporter under p53 responsive promoter of adenosine deaminase gene, plasmid expressing b-galactosidase and either the indicated plasmids or control pCDNA3 plasmid (empty vector). 0.1 mg of wild type p53 or K386R mutant in pCDNA3 and 0.9 mg of SUMO-1 in pCDNA3 were used. Total protein was made up to 2 mg with pCDNA3. Cell lysates were normalized by measuring b-galactosidase activity and by Western blotting to compare p53 levels with DO-1 antibodies. This was done to ensure that the same amount of p53 is present in each CAT assay. These results were the average of three independent sets of transfection. Shown below the chart is one out of three representative Western blots with DO-1 antibodies and anti-SUMO-1 antibodies on the same amount of cell lysate as was used for CAT assay. (b) CAT assay on cell lysates from Saos-2 co-transfected with pWafCAT reporter under p53 responsive promoter of WAF-1/p21 gene, plasmid expressing b-galactosidase, and either the indicated plasmids or control pCDNA3 plasmid (empty vector). 0.001 mg of wild type p53 or K386R mutant in pCDNA3 and 1.0 mg of SUMO-1in pCDNA3 or CMVp300 were used. Western blot with DO-1 antibodies on the same amount of cell lysate used for CAT assay, showing the levels of p53, is below the chart p53 modification by SUMO-1 SSS Kwek et al published observations and the results presented here con®rmed that a small fraction of p53 in cells is covalently bound to a single molecule of SUMO-1. Lysine 386 is the major sumoylation site, although the existence of other weaker sites is likely based on our in vitro and in vivo observations. The SUMO-1 modi®ed form of p53 increases following treatment with DNA-damaging agents. This observation suggested that SUMO-1 modi®cation could be involved in activation of p53's transactivation or DNA-binding activity. However, co-expression with SUMO-1 did not have any eect on the transactivation ability of p53. Since this result con¯icted with recently published observations (Rodriguez et al., 1999; Gostissa et al., 1999) , it could be explained by the dierences in experimental conditions used by dierent groups. However, we used the same cell line, Saos-2, the same amount of p53 (1 ng) and SUMO-1 (1 mg) expressing plasmids cited by one group (Rodriguez et al., 1999) and also a Waf-1-p53 responsive promoter which was used by the other group (Gostissa et al., 1999) . The only dierences were the method of transfection (lipofection instead of electroporation) and the type of reporter constructs (CAT instead of luciferase). It is unlikely that these experimental dierences would aect the results. Moreover, transactivition by p73, a p53 homologue which is also modi®ed by SUMO-1, is not increased by overexpression of SUMO-1 (Minty et al., 2000) . The authors mentioned that they also failed to see any eect of SUMO-1 on p53 transactivation.
Lack of eect of SUMO-1 in co-transfection experiments does not necessarily mean that sumoylated p53 has the same transactivating capacity as the wild type protein. It might simply re¯ect the fact that ectopic expression of SUMO-1 is insucient to increase the pool of SUMO-1-conjugated p53. By using the`activated' form of SUMO-1 (with deletion of the last four amino acids), we were able to increase the amount of SUMO-1 conjugated p53. This, however, still had no eect on transactivation by p53.
We can try to build a hypothesis about the potential biological function of sumoylation of p53 based on what is known about the eect of SUMO-1 on other proteins. For example, modi®cation of IkBa by SUMO-1 was shown to increase the half-life of the conjugated protein (Desterro et al., 1998) . It was recently shown that in vitro SUMO-1 modi®cation of Mdm2 abrogates its self-ubiquitination and also increases its stability (Buschmann et al., 2000) . It is, Figure 7a , except SUMO-4aa or SUMO-6aa was used in place of full-length SUMO-1. These results were the average from two independent sets of transfections. (c) Representative Western blotting with DO-1 on the same amount of cell lysate as was used for CAT assay Figure 9 K386R mutant is similar to wild type p53 in cell growth suppression assay. PCDNA3 (empty vector), pCDNA3 expressing p53 or the indicated mutants were transfected into Saos-2 cells. Twenty-four hours after transfection, the same number of cells (1/10 of original) were replated for each transfection and the rest were subjected to¯ow cytometry to quantitate the percentage of GFP positive cells: pCDNA3-17%, p53-15%, K292R-15.5%, K386R-17%, K292R/K386R-19% and K320R-21.5%. Cells were selected in G418 for about 2 weeks. The result shown is representative of three independent experiments therefore, reasonable to suspect that SUMO-1 modi®cation of p53 could also prevent its ubiquitination and increase the half-life of p53. Unfortunately, due to the small proportion of p53 that is being sumoylated, in contrast to the sumoylation of more than 50% of Mdm2, we were unable to detect any sumoylated p53 by 35 S-Methionine labeling in pulse-chase experiments and, therefore, could not address this question experimentally.
Another function of sumoylation seems to be the targeting of proteins to dierent cellular compartments. For example, RanGAP1 conjugated by SUMO-1 is localized at the nuclear membrane in nuclear pore complex, whereas the unconjugated form is found in the cytoplasm (Mahajan et al., 1997) . Modi®cation of PML by SUMO-1 targets it to PML bodies (Kamitani et al., 1998; Muller et al., 1998) and SUMO-1 modi®cation of HIPK2 correlates with its localization to nuclear speckles, which are distinct from PML bodies (Kim et al., 1999) . However, it was also shown that SUMO-1 modi®cation is not required for targeting SP100 (Sternsdorf et al., 1999) to PML bodies. We showed here that SUMO-1 conjugated p53 may be bound to chromatin structures. We also showed that p53 and SUMO-1 co-localize in PML nuclear bodies in 293 cells. Interestingly, p53 and SUMO-1 co-localized in the nucleoli in MCF7 and HT1080 cells. p53 also colocalized with SUMO-1 in the nucleoli in Saos-2 cells and H1299 cells by transient expression of p53, MDM2, and p14
Arf
, showing that this co-localization in the nucleoli is not a cell-type speci®c eect.
We hypothesized that p53 might be targeted to the nucleoli by SUMO-1 modi®cation. We transiently transfected K386R mutant in Saos-2 cells and H1299 cells and observed that it goes to the nucleoli in the presence of MDM2 and p14
Arf as wild type p53. Our results show that SUMO-1 modi®cation is not required for targeting p53 to the nucleoli. This suggests that p53 may be localized in the nucleoli by forming a complex with MDM2 and p14 Arf , independent of its sumoylation and may become sumoylated only after it has been localized in the nucleoli.
The alternative approach to address the biological function of p53 sumoylation is to compare properties of wild type and sumoylation-de®cient p53. No dierences were found between these proteins in p53 transactivation and growth suppression, again contradicting the previous reports that showed a slight decrease in apoptotic capacity of K386R p53 mutant (Muller et al., 2000) . To try and resolve this apparent con¯ict, we repeated all of the above experiments multiple times under a variety of conditions, such as modulating the amounts of p53 in transfection. All of the experiments gave reproducible negative results, showing that the biological eects of sumoylation of p53, at least at lysine 386, cannot be detected in these types of experiments.
Thus, we conclude that post-translational modi®ca-tion of p53 at lysine 386 by SUMO-1 may not be essential for p53 in mediating transcriptional activation, growth inhibition, and targeting to the nucleoli.
As mentioned before, there may be a weaker sumoylation site in p53, undetectable in the background of sumoylation at lysine 386. The lack of dierences between K386R mutant and wild type p53 might be because all sumoylation sites were not completely removed. We doubt that such a weak sumoylation of a very small quantity of p53 would play a major role. Nevertheless, additional lysine double mutants with K386R mutation might better address the biological signi®cance of sumoylation of p53.
Similar con¯icting results were observed when p53 mutants for individual, or all, phosphorylation sites were shown to render p53 less stable or less active by some groups (Unger et al., 1999; Fiscella et al., 1993) , but were shown to retain transactivation function by other groups (Blattner et al., 1999; Ashcroft et al., 1999; Fuchs et al., 1999) . This suggests that either the contribution of post-translational modi®cation is subtle, or that experimental systems, which cannot accurately recapitulate p53 expression, may fail to reveal the eects of such mutations. The ultimate resolution of the problem of biological signi®cance of post-translational modi®cation of p53 will probably require a`knock-in' experiment, which would allow one to analyse the phenotypes of animals with p53 that has been mutated at dierent modi®cation sites substituted for wild type p53.
Materials and methods

Yeast two-hybrid
Screening for interactors of p53 was carried out with the yeast two-hybrid system described by Finley and Brent (1995) . Mouse p53 deleted in the ®rst 72 amino acids, which comprised the transactivation domain, was used as bait. It was expressed as a fusion protein with DNA binding domain of LexA in pEG202 plasmid. Mouse brain cDNA library (complexity: 5610 6 , Clontech) expressed as fusion proteins with transactivation domain of B42 in JG4-5 plasmid was screened. Screening was carried out in yeast strain EGY48. Positive interactors were selected based on their ability to transactivate the LexA-operator-LEU2 gene and the LexAoperator-LacZ gene, which enabled the yeast to grow in the absence of leucine and form blue colonies in the presence of X-Gal respectively.
Cell culture and transfections
293 cells were maintained in 10% Fetal Clone Serum (Hyclone) in DMEM (Dulbecco's Modi®ed Eagle's Medium). Saos-2, H1299, MCF7, and HT1080 cells were maintained in 10% Fetal Bovine Serum (Hyclone) in DMEM. All transfections were carried out using Lipofectamine Plus as suggested by the manufacturer (Gibco ± BRL). Cruz Biotechnology, Inc. Paxillin monoclonal antibodies (349) were from Transduction Laboratories. SUMO-1 (GMP-1) monoclonal antibodies (21C7) were from Zymed. Anti-mouse and anti-rabbit horseradish peroxidase antibodies and normal mouse IgG were from Santa Cruz Biotechnology, Inc. Anti-mouse-FITC and anti-rabbit-TRITC antibodies and normal rabbit serum were from Sigma Chemical Co. Antirabbit-AMCA and avidin-Rhodamine antibodies were from Vector Laboratories, Inc. Histones H4 antiserum was a gift from CD Allis, Fibrillarin antiserum from KM Pollard (Reimer et al., 1987) , and ARF antiserum from KH Vousden (Bates et al., 1998) .
Western blotting
Cells were lysed in modi®ed RIPA buer without SDS (25 mM Tris HCl pH 7.2, 125 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 1 mM EDTA) or in SDS-containing buer (one part of SDS sample buer: 5% SDS, 0.15 M Tris HCl pH 6.7, 30% glycerol plus three parts of RIPA buer: 25 mM Tris pH 8.2, 50 mM NaCl, 0.5% Nonidet P40, 0.5% sodium deoxcholate, 0.1% SDS, 0.1% sodium azide) (Desterro et al., 1998) , containing 1 mM PMSF, 10 mg/ml of aprotinin and 10 mg/ml of leupeptin (Sigma Chemical Co). Cell lysates were incubated on ice for 15 min and centrifuged at 12 000 g for 10 min at 48C. Supernatants were transferred to new tubes. Protein concentration was quantitated with BioRad Dc protein assay, using BSA as a standard. Samples containing the same amount of protein were either run on 12 or 15% SDS ± PAGE, or on 4 ± 20% gradient SDS ± PAGE precast gels (Novex). Western blot was carried out as described in Amersham protocol for PVDF membrane.
Immunoprecipitation
Cells were collected in PBS, centrifuged, lysed in SDS-sample buer without dye (see Western blotting above) and diluted 10 times with PBS containing 0.5% NP40 (Desterro et al., 1998) with protease inhibitors. Cell lysates were incubated for 15 min on ice and centrifuged at 12 000 g for 10 min at 48C. Supernatants were incubated with 1 mg of DO-1 antibodies or normal mouse IgG for 1.5 h. Sepharose protein A (Gibco ± BRL) was added, incubated for 1 h and washed ®ve times with ice-cold PBS containing 0.5% NP40 and protease inhibitors. Proteins were eluted from sepharose beads by boiling in SDS ± sample buer. All steps were carried out at 48C with rocking unless stated otherwise.
Site-directed mutagenesis
The following primers were used for generating K292R mutant: Pair 1: 5'-atctacaagcagtcacagcacatgacggag-3'/5'-gtgaggctcccctcgcttgcggagattctc-3' Pair 2: 5'-gagaatctccgcaagcgaggggagcctcac-3'/SP6, 5'-catttaggtgacacta-3'. Primers for generating K386R mutant: Pair 1: 5'-aaaaggatccaccatggaggagccgcag-3'/5'-caggcccttctgtccggaacatgagttttt-3' Pair 2: 5'-aaaaactcatgttccggacagaagggcctg-3'/5'-aaacgaattctcagtctgagtcaggccc-3'.
Primers for generating K320R mutant: Pair 1: 5'-atctacaagcagtcacagcacatgacggag-3'/5'-catccagtggtttccgctttggctggggag-3' Pair 2: 5'-ctccccagccaaagcggaaaccactggatg-3'/SP6.
Underlined nucleotides correspond to the introduced mutations. PCR was carried out with each primer pair on wild type human p53 DNA in pCDNA3 to generate the respective mutation. Second PCR was carried out on a mixture of an equal amount of PCR products from the ®rst PCR reactions with sense primer of Pair 1 and antisense primer of Pair 2. PCR products from the second PCR reactions for K292R and K320R mutants were digested with Eco47III, and that for K386R mutant was digested with BamHI and EcoRI. Gel-purifed digested DNA fragments were cloned into human p53 in pCDNA3 or empty pCDNA3 vector for K386R mutant, digested with the respective enzymes. K292R/K386R double mutant was generated by carrying out site-directed mutagenesis with primers for generating K292R mutant using K386R mutant in pCDNA3 as the template. Clones were sequenced to con®rm mutations generated.
In vitro SUMO-1 conjugation assay
His-tagged SUMO-1 and UBC9 proteins were puri®ed from E. coli (BC21/DE3) carrying expression plasmid pETH-28 (Li et al., 2000) by using Ni2 + Kit (Novagen). Total HeLa cell extract were obtained by lysing 4610 7 cells in 1 ml of lysis buer (20 mM Tris HCl pH 7.5, 0.5 mM DTT, 5 mM NaF, 1 mM Na Orthovanadate, 1 mM PMSF, 5 mg/ml leupeptin, 10 mg/ml aprotinin) and incubated on ice for 15 min (Desterro et al., 1997) . Cells were disrupted with Dounce homogenizer with narrow clearance (type A) 30 times, and centrifuged at 12 000 g for 30 min. Supernatant was collected, glycerol was added to 10% and quick-frozen with dry ice/ ethanol mixture.
35
S-Met-labeled in vitro coupled transcription/translated (rabbit reticulocyte lysate, Promega) p53 or mutant proteins from pCDNA3 were incubated with 1 ml of 106 ATP regenerating system (500 mM Tris HCl pH 7.5, 50 mM MgCl 2 , 20 mM ATP, 100 mM Creatine phosphate, 35 U/ml Creatine kinase, 6 U/ml inorganic pyrophosphate), 5 ml of Hela cell extract, 5 mg of puri®ed SUMO-1, and 0.3 mg of puri®ed UBC9 in a ®nal volume of 10 ml. Incubation was carried out at 378C for 2 h. SDS sample buer was added to stop the reaction, samples were run on 4 ± 20% gradient gels and the dried gels were analysed by autoradiography.
Cell fractionation
Cell fractionation was carried out as described (Graham and Rickwood, 1997) with several modi®cations. 293 cells were washed twice with PBS and collected in PBS. Cells were centrifuged and washed once with Hypotonic wash buer (10 mM Tris HCl pH 7.4, 2 mM MgCl 2 , 10 mM KCl), and lysed with Hypotonic lysis buer (10 mM Tris HCl pH 7.4, 2 mM MgCl 2 , 10 mM KCl, 1 mM EGTA, 1 mM DTT and protease inhibitors) for 20 min on ice. Cell lysate was passed through a 25-gauge needle and crude nuclei were spun down at 700 g for 5 min. Crude nuclei were washed once with homogenizing medium (10 mM Tris HCl pH 7.4, 5 mM MgCl 2 , 0.25 M sucrose), resuspended in dense sucrose solution (10 mM Tris HCl pH 7.4, 1 mM MgCl 2 , 2.2 M sucrose) and homogenized for about six strokes with wide clearance (type B) Dounce homogenizer. Pure nuclei were recovered by centrifugation at 70 000 g in a Sorvall Ultracentrifuge. RNase/DNase treatment was carried out as for isolation of nuclear envelopes at low ionic strength as described (Graham and Rickwood, 1997 ) with the addition of 1 mg/ml of RNase A and DNase I. RNase/DNase treated nuclei were further fractionated by treatment with low salt (0.5 M NaCl), or high salt (2 M NaCl) in STM buer (10 mM Triethanolamine-HCl pH 7.4, 0.1 mM MgCl 2 , 1 mM DTT, 10% sucrose) for 5 min and centrifuged at 6500 g for 30 min (Snow et al., 1987) . All supernatants were collected and total protein was precipitated by adding an equal volume of 20% trichloroacetic acid and incubated for 30 min on ice.
Centrifugation was carried out at 12 000 g and pellets were washed once with ice-cold acetone. All samples were resuspended in SDS sample buer, boiled for 5 min and the supernatant for the same cellular proportions was run on 15% SDS ± PAGE. Protease inhibitors were added to all buers and all steps were carried out at 48C unless otherwise stated.
Indirect immunofluorescence
Cells were cultured in four chamber culture slides (Falcon). For triple staining, cells were washed once with PBS and ®xed in 4% paraformaldehyde for 5 min at RT, washed (Wash buer: 0.1 M Tris-HCl pH 7.5, 0.05 M NaCl, 0.05% Tween 20), and permeabilized in cold 50% acetone/50% methanol for 15 min at 7208C. For double staining, cells could also be ®xed as for triple staining or with Carnoy's Fixative (60% ethan, 30% chloroform, 10% glacial acetic acid) for 5 min at room temperature. After washing, cells were incubated in blocking buer (3% BSA in wash buer) for 30 ± 40 min at room temperature. Cells were then incubated with primary antibodies O/N at 48C or for 1 h at room temperature, washed three times, and incubated with the appropriate¯uorochrome-conjugated secondary antibodies. DAPI staining was used at a concentration of 0.1 mg/ml in PBS when required. Cells were covered in mounting media, Vectashield (Vector Laboratories, Inc.) and Gold Seal coverslips (Clay Adams). Confocal images were obtained using a Zeiss LSM510 laser scanning microscope. Dilution of primary antibodies: DO-1, 1 : 100; SUMO-1, 1 : 100 ± 1 : 50; p53-biotin, 1 : 50; PML, 1 : 100; Fibrillarin, 1 : 10. Dilution of secondary antibodies: anti-mouse-FITC, 1 : 64; anti-rabbit-TRITC, 1 : 32; anti-rabbit-AMCA, 1 : 50; Avidin-Rhodamine, 1 : 200.
Transactivation assay
0.5 mg of AdaCAT (chloramphenicol acetyl transferase) or pWafCAT plasmid with p53 responsive promoter from adenosine deaminase gene or Waf-1/p21 gene respectively (Kondratov et al., 1996) was used as the reporter. The reporter plasmid was co-transfected with 0.5 mg of pCMVlacZ expression plasmid, 0.001 or 0.1 mg of wild type or mutant p53 in pCDNA3 and 1.0 or 0.9 mg of SUMO-1 in pCDNA3. Total protein was made up to 2 mg with pCDNA3. Transfections were carried out with Lipofectamine Plus (Gibco ± BRL) in Saos-2 and H1299 cells in serum-free DMEM for 3 h. Cells were washed with PBS and 10%FBS in DMEM were added. Cells were lysed 36 h after transfection and normalized for transfection by quantitating b-galactosidase. Normalized cell extracts were run on 4 ± 20% SDS ± PAGE for Western blot analysis of p53 protein and used for standard CAT assay.
Growth suppression colony assay
For growth suppression assay, cells co-transfected with GFP (Green Fluorescence Protein) -expressing plasmids and wild type or mutant p53 in pCDNA3 were trypsinized 22 h after transfection. The same number of cells, about 1/10 of the total number, was replated and G418 was added after 24 h. Cells were maintained in G418 until colonies were obtained. Transfection eciency was determined by subjecting the rest of the cells to¯ow cytometery to quantitate the percentage of cells expressing GFP.
Abbreviations SUMO-1, Small Ubiquitin Modi®er 1; PML, Promyelocytic Leukemia Protein; CAT, chloramphenicol acetyl transferase; HA, hemagglutinin; NEM, N-ethylmaleimide; DMEM, Dulbecco's Modi®ed Eagle's Medium; PBS, phosphate-buered saline; DAPI, 4,6-diamidino-2-phenylindole; GFP, green¯uorescence protein.
